Kardani, K., Milani, A., H
Item #: NO346UPC: 733739000644 Elevate Your Energy Naturally
MS received research and consulting funding from Bayer, Bristol Myers Squibb, AstraZeneca, Janssen Global Services LLC, Alexion, Anthos and Novartis
Future pharmaceutical CagriSema Anticipated FDA approval: Phase 3 trials completed FDA submission expected 2024-2025 Approval likely 2025-2026 Brand name: CagriSema Pharmaceutical pricing (projected): Likely $1,200-1,500/month without insurance Similar to Wegovy/Zepbound pricing Insurance coverage uncertain initially Patient assistance programs may be available Insurance considerations: May cover if BMI 30 with comorbidity Or BMI 27 with diabetes/hypertension Prior authorization required Step therapy (try semaglutide first) When pharmaceutical available: Easier administration (pre-filled pen likely) Medical support included Quality guaranteed Prescription required May or may not be cheaper than research peptides Troubleshooting CagriSema dosing issues Common problems and solutions
86 HP 190 MAZDUTIDE GLP-1 + Glucagon Innovent ALIASES Mazdutide, IBI362, LY3305677 CLASS GLP-1/glucagon dual receptor agonist (Innovent/Lilly) FORMULA Synthetic peptide oxyntomodulin-derived HALF-LIFE ~7 days (once-weekly) ROUTES Subcutaneous (Phase 3 clinical) MECHANISM OF ACTION Innovent Biologics dual GLP-1 and glucagon receptor agonist (IBI362), derived from oxyntomodulin lineage
